Abstract
Cytokines are critical mediators of protective host responses, including defense against microbial invasion and tumorigenesis. However, the production of specific proinflammatory cytokines must be tightly regulated and compartmentalized to prevent the overzealous expression of these molecules that can culminate in unabated inflammation and tissue injury. Cytokine production and/or biologic effects can be inhibited by a variety of endogenous molecules, including anti-inflammatory cytokines, soluble cytokine receptors, and receptor antagonist proteins. Additionally, synthetic molecules have been constructed to selectively block the synthesis, post-translation processing, or receptor binding of proinflammatory cytokines. Relevant anti-inflammatory cytokines and cytokine inhibitors (both endogenous and synthetic) will be the subject of this review, with a particular emphasis on those anti-inflammatory cytokines and cytokine inhibitors that have been used experimentally or clinically in the treatment of diseases that are believed to be mediated by excessive proinflammatory cytokine responses.
Keywords: Antiinflammatory Cytokines, Antagonists, Microbial Invasion, tumorigenesis, receptor, proteins, endogenous synthetic, Regulation, Sepsis syndrome, rhematoid arthritis RA, Interleukin 4 IL4, autoimmune disease, Proinflammatory, Necrosis Factor, Pathogenesis, Blockade, Chemokines, Transcriptional factor Inhibitors
Current Pharmaceutical Design
Title: Anti-inflammatory Cytokines and Cytokine Antagonists
Volume: 6 Issue: 6
Author(s): Theodore J. Standiford
Affiliation:
Keywords: Antiinflammatory Cytokines, Antagonists, Microbial Invasion, tumorigenesis, receptor, proteins, endogenous synthetic, Regulation, Sepsis syndrome, rhematoid arthritis RA, Interleukin 4 IL4, autoimmune disease, Proinflammatory, Necrosis Factor, Pathogenesis, Blockade, Chemokines, Transcriptional factor Inhibitors
Abstract: Cytokines are critical mediators of protective host responses, including defense against microbial invasion and tumorigenesis. However, the production of specific proinflammatory cytokines must be tightly regulated and compartmentalized to prevent the overzealous expression of these molecules that can culminate in unabated inflammation and tissue injury. Cytokine production and/or biologic effects can be inhibited by a variety of endogenous molecules, including anti-inflammatory cytokines, soluble cytokine receptors, and receptor antagonist proteins. Additionally, synthetic molecules have been constructed to selectively block the synthesis, post-translation processing, or receptor binding of proinflammatory cytokines. Relevant anti-inflammatory cytokines and cytokine inhibitors (both endogenous and synthetic) will be the subject of this review, with a particular emphasis on those anti-inflammatory cytokines and cytokine inhibitors that have been used experimentally or clinically in the treatment of diseases that are believed to be mediated by excessive proinflammatory cytokine responses.
Export Options
About this article
Cite this article as:
Standiford J. Theodore, Anti-inflammatory Cytokines and Cytokine Antagonists, Current Pharmaceutical Design 2000; 6 (6) . https://dx.doi.org/10.2174/1381612003400533
DOI https://dx.doi.org/10.2174/1381612003400533 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Pharmaceutical Design Photooxygenation of Heterocycles
Current Organic Chemistry The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection
Current Drug Targets Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting Citrate Carrier (CIC) in Inflammatory Macrophages as a Novel Metabolic Approach in COVID-19 Patients: A Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endogenous Ligand Bias by Chemokines: Implications at the Front Lines of Infection and Leukocyte Trafficking
Endocrine, Metabolic & Immune Disorders - Drug Targets Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Combination of Fenofibrate with Non-Statin Drug Regimens
Current Pharmaceutical Design Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Preface
Current Pharmaceutical Design Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Controlled Gene Delivery Can Enhance Therapeutic Outcome for Cancer Immune Therapy for Melanoma
Current Gene Therapy Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Alamandine Induces Neuroprotection in Ischemic Stroke Models
Current Medicinal Chemistry An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide
Current Drug Safety Why Chemokines are Cytokines while their Receptors are not Cytokine Ones?
Current Medicinal Chemistry